# Antibody Drug Conjugates Market Expected to Reach $3.19 Billionsby 2023 | Current Trends and Industry Analysis

*Antibody drug conjugates market development strategies adopted by key manufacturers are enlisted to understand the competitive scenario.*

Antibody Drug Conjugates Market Share

PORTLAND, OREGON, UNITED STATES, October 27, 2023 /EINPresswire.com/ -- [Antibody drug conjugates market](#) accounted for $1,387 million in 2016, and is estimated to reach at $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023. Antibody drug conjugates are highly powerful biopharmaceutical medications prepared by integrating two principles i.e. a cell killing highly powerful active pharmaceutical ingredient (HPAPI) and explicit nature of monoclonal antibodies. They are highly effective anticancer drugs targeting only cancer infected cells thus, leaving healthy uninfected cell intact facilitating quick recovery of cancer patients.

□□□□ □□ □□□ □□□□□□□□ :
F. Hoffman-La Roche Ltd., ImmunoGen, Inc., Bayer AG, Novartis AG, Immunomedics, Inc., Agensys, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., Concortis Biotherapeutics, and NBE-Therapeutics.

□□□□□□□□ □□□□□□ □□□□□□ https://www.alliedmarketresearch.com/request-sample/1467

Increase in prevalence of cancer and rise in demand for efficient and cost-effective cancer treatments drive the market. Moreover, extensive research on drug development and large number of pipeline drugs for ADCs present in different stages of approvals are expected to boost the market growth. Approval of pipelined drugs increase the number of available ADC products, cumulatively spurring market turnover of ADCs. However, strict regulation set by regulating authorities for approval of ADCs and complications associated with drug development impedes the growth of antibody drug conjugates market. Growth in adoption of ADCs over conventional cancer treatments and rapidly developing market in Asia-Pacific & LAMEA create opportunities for market players.

North America holds the highest market share in 2016 owing to high prevalence of cancer in the region and modern healthcare facilities for employment of novel therapeutic procedures. Moreover, adoption of experimental medicines and growth in awareness about antibody drug conjugates in the region is expected to boost the North American market. However, Asia-Pacific region is expected to grow at the highest CAGR during the forecast period considering, high reported prevalence of cancer constituting a large patient pool.

□□□ □□□□□□□□□ □□□□□□□□ https://www.alliedmarketresearch.com/purchase-enquiry/1467

□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□ □□ □□□□ □□□□□□□:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

Comprehensive quantitative and qualitative insights at segment and sub-segment level

Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Winning imperatives

Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

---

This press release can be viewed online at: https://www.einpresswire.com/article/664486472